Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

What Was Tested

In this phase 2 trial, researchers set out to test Tirzepatide.

This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity.

It had 1 arm (groups): Adult survivors of childhood acute lymphoblastic leukemia (ALL) (experimental).

The registry classes the interventions as behavioral and drug.

More on the Plan

Secondary objectives include adherence to the intervention and changes in body composition, cardiometabolic health, and aging biomarkers.

Who Took Part

20 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: ≥5 years from diagnosis of acute lymphoblastic leukemia (ALL) treated with chemotherapy only. ≥2 years from completion of therapy. Participant has a negative (urine or blood) pregnancy test (if female). Age ≥18 years at the time of enrollment. Participant has obesity (BMI \> 30kg/m2) or overweight (BMI \> 27kg/m2) with ≥1 weight related co-morbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).

The full record lists 9 inclusion and 31 exclusion criteria; among the exclusions: xenical®/alli® (orlistat); meridia® (sibutramine); acutrim® (phenylpropanolamine).

How the Study Was Run

Design: single-group and open-label.

Nothing was hidden in this open-label Tirzepatide study: the participants and staff both knew the treatment.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2026-04-23 with completion listed for 2027-11.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

It also tracked 2 secondary outcomes, for example To estimate the proportion of participants who adhere to the 28-week combined intervention and To estimate the average percentage weight loss from week 0 to 28 for participants completing the combined 28-week intervention.

What This Means in Plain Language

Put simply, this is a phase 2 trial of Tirzepatide in 20 people.

Its size is small, so on its own it can only give an early look.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.